semaglutide and cardiovascular disease SELECT Trial 6 semaglutide Cardiovascular risk reduction

Available from URL: www.cochrane.org/handbook (accessed January 2026) Balduzzi S, Rcker G, Schwarzer G

Unintended consequences of obesity pharmacotherapy: a nutritional approach to ensuring better patient outcomes

Today's oral GLP-1s give 13-15% weight loss at 36 weeks (orforglipron Phase 2)

25 mg: 1.8% (20 mmol/mol)

The GIP receptor is a seven-transmembrane G protein-coupled receptor strongly expressed on islet cells, which has been found in many tissues including the pancreas, adipose tissue, heart, gastrointestinal tract, adrenal cortex, and various neurons in the brain [99]

Labs and Consultation After labs youll have a free consultation with one of our medical Providers online or in the office